Cargando…

Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation

BACKGROUND: The optimal therapy of patients with acute subsegmental pulmonary embolism (PE) is controversial. METHODS: We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to compare the rate of symptomatic PE recurrences during anticoagulation in patients with subsegmental,...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández‐Capitán, Carmen, Rodriguez Cobo, Ana, Jiménez, David, Madridano, Olga, Ciammaichella, Maurizio, Usandizaga, Esther, Otero, Remedios, Di Micco, Pierpaolo, Moustafa, Farès, Monreal, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845079/
https://www.ncbi.nlm.nih.gov/pubmed/33537541
http://dx.doi.org/10.1002/rth2.12446
_version_ 1783644484305682432
author Fernández‐Capitán, Carmen
Rodriguez Cobo, Ana
Jiménez, David
Madridano, Olga
Ciammaichella, Maurizio
Usandizaga, Esther
Otero, Remedios
Di Micco, Pierpaolo
Moustafa, Farès
Monreal, Manuel
author_facet Fernández‐Capitán, Carmen
Rodriguez Cobo, Ana
Jiménez, David
Madridano, Olga
Ciammaichella, Maurizio
Usandizaga, Esther
Otero, Remedios
Di Micco, Pierpaolo
Moustafa, Farès
Monreal, Manuel
author_sort Fernández‐Capitán, Carmen
collection PubMed
description BACKGROUND: The optimal therapy of patients with acute subsegmental pulmonary embolism (PE) is controversial. METHODS: We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to compare the rate of symptomatic PE recurrences during anticoagulation in patients with subsegmental, segmental, or more central PEs. RESULTS: Among 15 963 patients with a first episode of symptomatic PE, 834 (5.2%) had subsegmental PE, 3797 (24%) segmental, and 11 332 (71%) more central PE. Most patients in all subgroups received initial therapy with low‐molecular‐weight heparin, and then most switched to vitamin K antagonists. Median duration of therapy was 179, 185, and 204 days, respectively. During anticoagulation, 183 patients developed PE recurrences, 131 developed deep vein thrombosis (DVT), 543 bled, and 1718 died (fatal PE, 135). The rate of PE recurrences was twofold higher in patients with subsegmental PE than in those with segmental (hazard ratio [HR], 2.13; 95% confidence interval [CI], 1.16‐3.85) or more central PE (HR, 1.89; 95% CI, 1.12‐3.13). On multivariable analysis, patients with subsegmental PE had a higher risk for PE recurrences than those with central PE (adjusted HR, 1.75; 95% CI, 1.02‐3.03). After stratifying patients with subsegmental PE according to ultrasound imaging in the lower limbs, the rate of PE recurrences was similar in patients with DVT, in patients without DVT, and in those with no ultrasound imaging. CONCLUSIONS: Our study reveals that the risk for PE recurrences in patients with segmental PE is not lower than in those with more central PE, thus suggesting that the risk of PE recurrences is not influenced by the anatomic location of PE.
format Online
Article
Text
id pubmed-7845079
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78450792021-02-02 Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation Fernández‐Capitán, Carmen Rodriguez Cobo, Ana Jiménez, David Madridano, Olga Ciammaichella, Maurizio Usandizaga, Esther Otero, Remedios Di Micco, Pierpaolo Moustafa, Farès Monreal, Manuel Res Pract Thromb Haemost Original Articles ‐ Thrombosis BACKGROUND: The optimal therapy of patients with acute subsegmental pulmonary embolism (PE) is controversial. METHODS: We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to compare the rate of symptomatic PE recurrences during anticoagulation in patients with subsegmental, segmental, or more central PEs. RESULTS: Among 15 963 patients with a first episode of symptomatic PE, 834 (5.2%) had subsegmental PE, 3797 (24%) segmental, and 11 332 (71%) more central PE. Most patients in all subgroups received initial therapy with low‐molecular‐weight heparin, and then most switched to vitamin K antagonists. Median duration of therapy was 179, 185, and 204 days, respectively. During anticoagulation, 183 patients developed PE recurrences, 131 developed deep vein thrombosis (DVT), 543 bled, and 1718 died (fatal PE, 135). The rate of PE recurrences was twofold higher in patients with subsegmental PE than in those with segmental (hazard ratio [HR], 2.13; 95% confidence interval [CI], 1.16‐3.85) or more central PE (HR, 1.89; 95% CI, 1.12‐3.13). On multivariable analysis, patients with subsegmental PE had a higher risk for PE recurrences than those with central PE (adjusted HR, 1.75; 95% CI, 1.02‐3.03). After stratifying patients with subsegmental PE according to ultrasound imaging in the lower limbs, the rate of PE recurrences was similar in patients with DVT, in patients without DVT, and in those with no ultrasound imaging. CONCLUSIONS: Our study reveals that the risk for PE recurrences in patients with segmental PE is not lower than in those with more central PE, thus suggesting that the risk of PE recurrences is not influenced by the anatomic location of PE. John Wiley and Sons Inc. 2020-11-18 /pmc/articles/PMC7845079/ /pubmed/33537541 http://dx.doi.org/10.1002/rth2.12446 Text en © 2020 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH). This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles ‐ Thrombosis
Fernández‐Capitán, Carmen
Rodriguez Cobo, Ana
Jiménez, David
Madridano, Olga
Ciammaichella, Maurizio
Usandizaga, Esther
Otero, Remedios
Di Micco, Pierpaolo
Moustafa, Farès
Monreal, Manuel
Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation
title Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation
title_full Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation
title_fullStr Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation
title_full_unstemmed Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation
title_short Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation
title_sort symptomatic subsegmental versus more central pulmonary embolism: clinical outcomes during anticoagulation
topic Original Articles ‐ Thrombosis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845079/
https://www.ncbi.nlm.nih.gov/pubmed/33537541
http://dx.doi.org/10.1002/rth2.12446
work_keys_str_mv AT fernandezcapitancarmen symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation
AT rodriguezcoboana symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation
AT jimenezdavid symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation
AT madridanoolga symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation
AT ciammaichellamaurizio symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation
AT usandizagaesther symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation
AT oteroremedios symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation
AT dimiccopierpaolo symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation
AT moustafafares symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation
AT monrealmanuel symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation
AT symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation